Orexigen (OREX) Tumbling on FDA Delay for New Obesity Drug

Jianyu Zhao | |

Shares of Orexigen Therapeutics (OREX) fell 14.68 percent to $5.81 on June 11, after the company announced that the Food and Drug Administration (FDA) decided to delay the review of its new drug

Understanding the Impact of Clinical Trials on Shareholder Value

Andrew Klips | |

Clinical trial data can move a stock price like virtually nothing else on Wall Street. Given the proclivity for volatility, investing in small- and mid-cap biotech is definitely not for the faint

Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers

The Life Sciences Report | |

Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and

Stocks Mostly Flat After NASDAQ Tops 4,000 for First Time in 13 Years

Michael Teague | |

After a strong start, stocks pared back the day’s gains in late-session Monday, but still ended mostly higher after the NASDAQ exchange topped 4,000 points for the first time in 13

Orexigen Shares Jump on NDA Submission for Weight Loss Drug

Andrew Klips | |

Orexigen Therapeutics, Inc. (OREX) and Takeda Pharmaceuticals are hoping that the re-submission of a New Drug Application for a weight loss drug to the U.S. Food and Drug Administration will

Is Clovis Oncology Riding a Biotech Bull?

Michael Teague | |

Shares for Clovis Oncology (CLVS) are currently in their second straight day of over 10 percent gains. Last Friday, the company’s stock gained 15.6 percent to close at $21.81, and Monday saw

Stocks Under $10: More Hold-Rated Biomed/Genetics in the Medical Sector

Richard Suttmeier | |

At we show that the Medical sector 12.1% overvalued with the Medical Biomed / Genetics 13.7% overvalued. All 17 stocks in today’s table have complete ValuEngine data and have

Equities Sector Coverage: Bulls Get the Green Light

Sector Recap | |

Initial Jobless Claims fell 12,000 to 365,000 still above the 350,000 recessionary threshold. Non-manufacturing ISM came in at 53.7 in August, just above expectations. The Dow Jones Industrial

Equities Sector Coverage: Stocks Close Out Strong First Quarter

Sector Recap | |

Personal Income rose by just 0.2% in February with Spending up 0.8%. This brings the Savings Rate down to 3.7%, the lowest since August 2009. The year over year PCE Price Index was up 2.3%, above

Equities Sector Coverage: Stocks Pare Gains to Close Flat

Sector Recap | |

The Dow Jones Industrial Average traded between the narrow range of 12920 and 12976; ending the day above the 21- day simple moving average at 12920, which shifts the daily cycle to positive. The

Sponsored Financial Content

Market Movers